임상시험 장비 및 부속 솔루션 시장 : 유형별, 서비스별, 최종사용자별 - 세계 예측

Clinical Trial Equipment and Ancillary Solutions Market is projected to accrue 7.5% CAGR from 2024 to 2032, driven by increasing partnerships for driving innovations and expanding access to advanced technologies. Companies are joining forces to integrate diverse expertise and resources for enhancing the development and deployment of trial equipment, such as remote monitoring devices and specialized diagnostic tools. These collaborations are also improving trial efficiency and patient outcomes for leveraging combined strengths in research and technology. For instance, in May 2024, Clario, a healthcare research and technology company, announced a strategic partnership with Emsere, a prominent supplier of medical equipment for clinical trials, to enhance clinical trial equipment and ancillary solutions through combined expertise and resources.

The overall market is segregated into type, service, end-user, and region.

In terms of type, the clinical trial equipment and ancillary solutions market from the laboratory instruments segment is expected to witness significant CAGR from 2024 to 2032 due to the increasing innovations, such as automated sample processing and high-throughput analysis systems. These instruments are enabling more efficient data collection and analysis for enhancing the precision and reliability of clinical trials. Companies are also integrating cutting-edge technologies, such as AI for real-time data analysis and predictive modeling to optimize laboratory workflows and improve research outcomes.

By End-User, the clinical trial equipment and ancillary solutions industry from the biotechnology companies segment is projected to rise from 2024 to 2032 led by higher adoption of cutting-edge technologies, such as gene therapy tools and advanced diagnostic platforms. These companies are enhancing their research capabilities to develop personalized treatments and targeted therapies to improve patient outcomes and healthcare efficacy. Collaborations with academic institutions and healthcare providers are also driving advancements in biotechnology for facilitating more precise clinical trials while accelerating the development of novel medical solutions.

Regionally, the Asia Pacific clinical trial equipment and ancillary solutions market size is projected to exhibit robust growth between 2024 and 2032, fueled by the rising chronic diseases and advancements in healthcare. Technologies, such as remote monitoring devices and digital health platforms are increasingly adopted to improve patient care and research efficacy. These advancements are enhancing the capability to conduct complex clinical trials and gathering real-time health data for facilitating better disease management and treatment outcomes in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Globalization of clinical trials
    • 3.2.1.2 Growing demand for outsourcing clinical trials to CROs
    • 3.2.1.3 Rise in government and non-government funding for clinical trials
    • 3.2.1.4 Focus on patient-centric trials
    • 3.2.1.5 Growing technology advancements
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Complex and stringent regulatory requirements
    • 3.2.2.2 Limited infrastructure in developing countries
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Clinical trial volume, by region
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Diagnostic equipment
• 5.3 Laboratory instruments
• 5.4 Ancillary solutions

Chapter 6 Market Estimates and Forecast, By Service, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Rental & leasing services
• 6.3 Supply and logistics services
• 6.4 Regulatory compliance services
• 6.5 Software services

Chapter 7 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Pharmaceutical & biotechnology companies
• 7.3 Contract research organizations (CROs)
• 7.4 Medical device companies
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 The Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Andwin Scientific
• 9.2 Ancillare, LP.
• 9.3 AXELERIST FINANCIAL
• 9.4 Biocair
• 9.5 ICON plc
• 9.6 Imperial CRS, LLC.
• 9.7 Marken
• 9.8 MESM UK.
• 9.9 Myonex
• 9.10 NUVISAN
• 9.11 Oximio
• 9.12 Parexel International (MA) Corporation
• 9.13 Quipment SAS
• 9.14 Thermo Fisher Scientific Inc.